Pacmilimab
Based on 1 Customer Validation
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.00%
- CAS. Nr.: 2145091-51-4
- Molecular Weight:152.6 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P9902
PembrolizumabPD-1 Inhibitor -
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-P9903
NivolumabPD-1 Inhibitor -
HY-P9919
DurvalumabPD-L1 Blocking Antibody -
HY-P99052
TislelizumabPD-1 Inhibitor -
HY-P9978
ToripalimabPD-1 Inhibitor -
HY-108730
AvelumabAnti-PD-L1 Antibody -
HY-P99048
SintilimabPD-1/PD-L1 Inhibitor -
HY-P9919A
Durvalumab (anti-PD-L1)PD-1/PD-L1 Inhibitor -
HY-P9971
CamrelizumabPD-1 Neutralizing Antibody -
HY-P99203
CemiplimabPD-1 Inhibitor -
HY-P99118
SerplulimabAnti-PD-1 Antibody
Biologische Aktivität
Beschreibung
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
B7-H1/PD-L1/CD274
In Vivo
Pacmilimab accumulates in murine PD-L1-expressing tumors with minimal uptake in peripheral, non-cancerous lymphoid tissue, consistent with limited uptake in non-tumor PD-L1-expressing tissues and protection against autoimmunity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 2145091-51-4
-
Appearance Liquid
-
Molecular Weight 152.6 kDa
-
Color Colorless to light yellow
-
SMILES
[Pacmilimab]
-
Synonyms
CX-072
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Reinheit & Dokumentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Pacmilimab Related Classifications
HY-P99799 Related Classifications
Powered by Bioz